GE Healthcare Invests in Homecare Ultrasound Firm Pulsenmore

GE Healthcare will invest up to $50 million in Israeli startup Pulsenmore, a developer of homecare ultrasound solutions. The investment aims to help Pulsenmore pursue FDA clearance and commercial growth. GE will also help distribute the company’s products in Europe and other markets as the product becomes available.
 
Pulsenmore’s novel self-operated prenatal home ultrasound combines with a smartphone to help pregnant women self-scan for remote clinical assessment.
 
The offering includes a handheld ultrasound that docks with the user’s smartphone, a mobile app for consultation, a web application for clinician interaction, and a software API for integration of online services with health records.
 
The periodic fetal ultrasound scanning and consultation can be offered as a clinician-guided telecom service or offline, application-guided service.
 
“Our agreement with GE Healthcare is a resounding vote of confidence in our ultrasound technology and our company, Pulsenmore founder and CEO Dr. Elazar Sonnenschein told the press. “With GE Healthcare’s market leadership position and reach, we are one step closer to achieving our vision of making home ultrasound universally accessible for remote and reliable care, ultimately improving maternal health across the globe. Through this exciting partnership, we will accelerate the empowerment of women to proactively manage their pregnancy, in collaboration with their health care providers, and will lead the next wave of ultrasound innovation that will benefit patients and providers alike.”
 
GE Healthcare Ultrasound president and CEO Roland Rott added, “Healthcare providers are predicting a significant shift of care services from traditional facilities to the home, which will require an increase in the level of quality or access. Homecare opens the door to tremendous value for payers, healthcare facilities, physician groups and care-at-home providers, with the opportunity to improve patients’ quality of care and experience. We also recognize the desire of patients—in this case, pregnant women—to be more empowered and involved in their healthcare. This is precisely why we are investing in Pulsenmore’s innovative homecare ultrasound technology. We are excited about adding this highly complementary offering to our market leading Women’s Health and Primary Care standard of care ultrasound diagnostics solutions, marking a strong step forward in enabling precision health.”
 
Pulsenmore is also developing remote follicular monitoring for women undergoing in-vitro fertilization, as well as remote monitoring for chronic heart failure and end-stage renal disease.